Molecules and mechanisms of the graft-versus-leukaemia effect

Nature Reviews Cancer

Volumn 4, Issue 5, 2004, Pages 371-380

  Bleakley, Marie ^a   Riddell, Stanley R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN RECOGNITION; CANCER STAGING; CELL SPECIFICITY; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNE SYSTEM; IMMUNOREACTIVITY; LEUKEMIA; LEUKEMIA CELL; NONHUMAN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR CELL DESTRUCTION;

EID: 2342484524     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1365     Document Type: Review

References (102)

1. Appelbaum, F. R. The current status of hematopoietic cell transplantation. Annu. Rev. Med. 54, 491-512 (2003).
2. Klein, J. & Sato, A. The HLA system. N. Engl. J. Med. 343, 702-709 (2000).
3. Vogelsang, G. B., Lee, L. & Bensen-Kennedy, D. M. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu. Rev. Med. 54, 29-52 (2003).
4. Falkenburg, J. H., van de Corput, L., Marijt, E. W. & Willemze, R. Minor histocompatibility antigens in human stem cell transplantation. Exp. Hematol. 31, 743-751 (2003).
5. Barnes, D. W. H., Corp, M. J., Loutit, J. F. & Neal, F. E. Treatment of murine leukemia with x-rays and homologous bone marrow. Br. Med. J. 32, 626-627 (1956).
6. Weiden, P. L. et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300, 1068-1073 (1979).
7. Horowitz, M. M. et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555-562 (1990).
8. Marmont, A. M. et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78, 2120-2130 (1991).
9. Passweg, J. R. et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 21, 153-158 (1998).
10. Kolb, H. J. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86, 2041-2050 (1995).
11. Collins, R. H. Jr et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15, 433-444 (1997).
12. Storb, R. et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 69, 3048-3054 (1997).
13. Khouri, I. F. et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98, 3595-3599 (2001).
14. Champlin, R. et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br. J. Haematol. 111, 18-29 (2000).
15. Maloney, D. G. et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102, 3447-3454 (2003).
16. Maris, M. B. et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102, 2021-2030 (2003).
17. Childs, R. et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343, 750-758 (2000).
18. Mielcarek, M. et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102, 758-762 (2003).
19. Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002).
20. Parham, P. & McQueen, K. L. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nature Rev. Immunol. 3, 108-122 (2003).
21. + T cells specific for a single minor histocompatibility antigen.
22. Warren, E. H., Greenberg, P. D. & Riddell, S. R. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 91, 2197-2207 (1998).
23. Falkenburg, J. H. et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J. Exp. Med. 174, 27-33 (1991).
24. + cytotoxic T cells.
25. den Haan, J. M. et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279, 1054-1057 (1998).
26. Mommaas, B. et al. Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J. Immunol. 169, 3131-3136 (2002).
27. den Haan, J. M. et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268, 1476-1480 (1995). Describes the use of peptide elution, high-performance liquid chromatographic fractionation and mass spectrometry to identify the molecular structure of the first human minor histocompatibility antigen.
28. Pierce, R. A. et al. The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J. Immunol. 167, 3223-3230 (2001).
29. Spierings, E. et al. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood 102, 621-629 (2003).
30. Brickner, A. G. et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J. Exp. Med. 193, 196-206 (2001).
31. Dolstra, H. et al. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J. Immunol. 158, 560-565 (1997).
32. Dolstra, H. et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J. Exp. Med. 189, 301-308 (1999).
33. Murata, M., Warren, E. H. & Riddell, S. R. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J. Exp. Med. 197, 1279-1289 (2003).
34. Akatsuka, Y. et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J. Exp. Med. 197, 1489-1500 (2003).
35. Wang, W. et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 269, 1588-1590 (1995).
36. Meadows, L. et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6, 273-281 (1997).
37. Pierce, R. A. et al. Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. J. Immunol. 163, 6360-6364 (1999).
38. Vogt, M. H. et al. UTY gene codes for an HLA-B60-restricted human male-specific minor histocompatibility antigen involved in stem cell graft rejection: characterization of the critical polymorphic amino acid residues for T-cell recognition. Blood 96, 3126-3132 (2000).
39. Warren, E. H. et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J. Immunol. 164, 2807-2814 (2000).
40. Vogt, M. H. et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 99, 3027-3032 (2002).
41. + T-helper cells in H-Y-mismatched transplantation. Lancet 362, 610-615 (2003).
42. Teshima, T. et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Med. 8, 575-581 (2002).
43. Goulmy, E. et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 334, 281-285 (1996).
44. Mutis, T. et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nature Med. 5, 839-842 (1999).
45. Lin, M. T. et al. Absence of statistically significant correlation between disparity for the minor histocompatibility antigen-HA-1 and outcome after allogeneic hematopoietic cell transplantation. Blood 98, 3172-3173 (2001).
46. Murata, M. et al. No significant association between HA-1 incompatibility and incidence of acute graft-versus-host disease after HLA-identical sibling bone marrow transplantation in Japanese patients. Int. J. Hematol. 72, 371-375 (2000).
47. + cytotoxic T cells specific for HA-1 and HA-2.
48. Kircher, B. et al. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br. J. Haematol. 117, 935-939 (2002).
49. Nagy, B. et al. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br. J. Haematol. 120, 434-441 (2003).
50. Dolstra, H. et al. Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. Eur J. Immunol. 32, 2748-2758 (2002).
51. Phillips, R. L. et al. The genetic program of hematopoietic stem cells. Science 288, 1635-1640 (2000).
52. Nielsen, M. et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12, 1007-1017 (2003).
53. Akatsuka, Y. et al. Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br. J. Haematol. 123, 671-675 (2003).
54. Dickinson, A. M. et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nature Med. 8, 410-414 (2002).
55. Randolph, S. S., Gooley, T. A., Warren, E. H., Appelbaum, F. R. & Riddell, S. R. Female donors contribute to a selective graft versus leukemia effect in male recipients of HLA matched related hematopoietic cell transplants. Blood 103, 347-352 (2004).
56. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95, 2198-2203 (2000).
57. Molldrem, J. et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88, 2450-2457 (1996).
58. Andersen, M. H. et al. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 61, 5964-5968 (2001).
59. Arai, J. et al. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97, 2903-2907 (2001).
60. Maecker, B. et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 102, 3287-3294 (2003).
61. Siegel, S. et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 102, 4416-4423 (2003).
62. Scharnhorst, V., van der Eb, A. J. & Jochemsen, A. G. WT1 proteins: functions in growth and differentiation. Gene 273, 141-161 (2001).
63. Inoue, K. et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89, 1405-1412 (1997).
64. + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 102, 2892-2900 (2003).
65. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95, 286-293 (2000).
66. Azuma, T. et al. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br. J. Haematol. 118, 601-603 (2002).
67. Gao, L. et al. Human cytotoxic T lymphocytes specific for Wilms' tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 75, 1429-1436 (2003).
68. Williams, R. C. Jr et al. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. J. Immunol. 152, 4722-4737 (1994).
69. Dangler, R. et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br. J. Haematol. 89, 250-257 (1995).
70. Molldrem, J. J. et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 90, 2529-2534 (1997).
71. Molldrem, J. J., Lee, P. P., Wang, C., Champlin, R. E. & Davis, M. M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59, 2675-2681 (1999).
72. Molldrem, J. J. et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111, 639-647 (2003).
73. + T cells specific for proteinase 3 - a protein expressed in normal myeloid differentiation and overexpressed in chronic myeloid leukaemia - are expanded in patients with leukaemia that respond to interferon-α therapy or allogeneic stem-cell transplantation.
74. Burchert, A. et al. Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101, 259-264 (2003).
75. Riddell, S. R. et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238-241 (1992).
76. Walter, E. A. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038-1044 (1995).
77. Heslop, H. E. et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med. 2, 551-555 (1996).
78. Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumour lymphocytes. Science 298, 850-854 (2002). Shows that the use of non-myeloablative chemotherapy to induce lymphopaenia allows for dramatic in vivo expansion and clonal repopulation of adoptively transferred T cells specific for differentiation antigens expressed in melanoma. This therapy was associated with tumour regression and autoimmune destruction of normal melanocytes in some patients.
79. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumour effect of transferred T cells. Proc. Natl Acad. Sci. USA 99, 16168-16173 (2002).
80. Mutis, T. et al. Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA. Biol. Blood Marrow Transplant. 8, 412-419 (2002).
81. Osman, Y. et al. Generation of bcr-abl specific cytotoxic T-lmphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 13, 166-174 (1999).
82. Osman, Y. et al. Dendritic cells stimulate the expansion of PML-RARα specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J. Exp. Clin. Cancer Res. 18, 485-492 (1999).
83. Yee C. et al. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162, 2227-2234 (1999).
84. Becker C. et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nature Med. 7, 1159-1162 (2001).
85. Brodie, S. J. et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nature Med. 5, 34-41 (1999).
86. Lu, J. et al. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumour cytotoxic T lymphocytes. Clin. Cancer Res. 8, 3877-3884 (2002).
87. Cooper, L. J., Kalos, M., Lewinsohn, D. A., Riddell, S. R. & Greenberg, P. D. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. 74, 8207-8212 (2000).
88. Stanislawski, T. et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nature Immunol. 2, 962-970 (2001).
89. Heemskerk, M. H. et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood 102, 3530-3540 (2003).
90. Dudley, M. E. & Rosenberg, S. A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nature Rev. Cancer 3, 666-675 (2003).
91. Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Med. 9, 279-286 (2003).
92. Sallusto, F. & Lanzavecchia, A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol. Rev. 177, 134-140 (2000).
93. + hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 91, 4523-4530 (1998).
94. + T cells specific for a skin-tropic virus. J. Clin. Invest. 110, 537-548 (2002).
95. Hacein-Bey-Abina, S. et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255-256 (2003).
96. Bonini, C. et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724 (1997).
97. Riddell, S. R. et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med. 2, 216-223 (1996).
98. Thomis, D. C. et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97, 1249-1257 (2001).
99. Berger, C. et al. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood 103, 1261-1269 (2003).
100. Chen, B. J., Cui, X., Sempowski, G. D., Liu, C. & Chao, N. J. Transfer of allogeneic CD62L-memory T cells without graft-versus-host disease. Blood 103, 1534-1541 (2003).
101. + T cells do not induce graft-versus-host disease. J. Clin. Invest. 112, 101-108 (2003).
102. Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423-1432 (2003).